Friday, 15 Dec 2017

You are here

The ACR17 RheumNow Week in Review - 1 December 2017

Dr Jack Cush reviews nighlights and news from the past 2 weeks on RheumNow.com. This week's report includes new drug approvals, disappointing ACR guidelines, Lyme & Zika, infertility, dermatomyositis skin outcomes and myositis-associated cancer testing.

  1. 45% Pharmacists & 35% Nurses say they receive TEXT orders every day (20%) or >1/wk (35%), yet only 12% said texting… https://t.co/rxo1P2A7mP 
  2. Claims data analyses shows infertile men have higher rates of developing rheumatoid arthritis, multiple sclerosis, psoriasis, thyroiditis, and Grave's disease. https://t.co/6vxMMp54IZ
  3. Hippocrates advises that an ice cube on the skin for 2 min substantially reduces the sting (pain) of a subcutaneous… https://t.co/Ik9dpZgAMV
  4. Metanalysis of 4 RCTs involving 287 patients with chronic widespread pain revealed Vitamin D therapy yielded no sigificant change in VAS… https://t.co/pfBhpqmKHx
  5. In Pre-Clinical RA pts, ACPA pos & ACPA neg behave differently. ACPA pos pts had longer duration of sxs initially but shorter time to arthritis (median 6 vs 18 weeks, p=0.015) than ACPA neg people.  ACPA negative had less  lower extremity Sxs (22% vs 50%)  https://t.co/5hPsYm1NPc
  6. FDA approved rheumatology drugs in 2017: Brodalumab (Siliq); oral Methotrexate solution (Xatmep): Abaloparatide (Tymlos); Tocilizumab (Acterma) GCA: Sarilumab (Kevzara); Guselkumab (Tremfya); Sc Belimumab (Benlysta); Lesinurad w/ allopurinol (Duzallo) https://t.co/CWToiMvidA
  7. Gout risk assoc with Soda & high fructose corn syrup. New NHANES study shows 1209 young adults, 20–30 yrs enrolled 2003–2006 who drank >4 sodas/HFCS drinks per week had a significant 3 fold higher rate of ARTHRITIS.  Risk was not assoc. w/ diet sodas https://t.co/Z8qvW3FgAE
  8. Cancer and myositis significantly increased by Autoantibodies to TIF1-(SIR = 17.28), NXP2 (8.14), SAE1 (12.9) & MSA neg pts (3.99); but not assoc. w/ anti-HMGCR, anti-MDA5 or Myositis specific Abs (Jo-1, PL-7, PL-12, Mi-2, SRP, PL-7, anti-E or anti-OJ) https://t.co/ZZwXzgVvFa
  9. Low energy extracorporeal shock wave therapy shown to successfully treats finger ulcers in scleroderma patients… https://t.co/HNnF7yh7IK
  10. FDA issued safety warning & is investigating Limbrel over 194 adverse event reports regarding Limbrel causing life-threatening drug-induced liver injury and hypersensitivity pneumonitis. Limbrel is a flavinoid nutraceutical used for osteoarthritis https://t.co/1ixhfKbBFu
  11. NY Times review shows physicians spend more time on the EMR than time spent with patients (sometimes twice as much!… https://t.co/F02FoqKh3j
  12. New CDC surveillance report shows the top 7 states for Lyme disease in 2015 include 1) Vermont (78.4/100000/yr); 2)… https://t.co/PaQZgDaWAm
  13. Map of Lyme Disease in the USA 2008-2015. Leading the way : VT, ME, PA, RI, CT, NJ, MA. https://t.co/oUeqT6IfKB https://t.co/49OiOIk64X
  14. New data shows chloroquine may be effective in Rx of Zika virus by markedly reducing amount of Zika virus in matern… https://t.co/CyOVYROGG1 
  15. @JAMADerm: Study shows that less than 40% of #dermatomyositis patients achieve skin remission even w aggressive treatment https://t.co/8
  16. Strawberry Gingivitis associated with Granulomatosis with Polyangiitis. 42 yo w/ epistaxis, painful gingival hyperp… https://t.co/QGoEVjBdWB
  17. FDA approves Fasenra (benralizumab) that binds to the IL-5α receptor, and depletes eosinophils rapidly. Indicated… https://t.co/2CD3qhAzvO 
  18. ACR Clinical Guidelines Flawed by Low Evidence 
  19. Prevalence of Arthritis Grossly Underestimated 
  20. RheumNow ACR 2017 Awards   

 

Disclosures: 
The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

The RheumNow Week in Review - 15 December 2017

Dr. Jack Cush reviews the news from the past week on RheumNow.com. Subscribe to the podcast on iTunes and SoundCloud.com. 

The RheumNow Week in Review - 8 December 2017

Dr. Jack Cush covers the news and journal articles published on RheumNow.comin the past week.

Rheumatology Year in Review

During 2017, the improvements and refinements seen during previous years in the treatment of rheumatoid arthritis have been extending to other conditions ranging from psoriatic arthritis to lupus and for both monoclonal antibodies and oral small molecule medications.

Advances for Biologics

ACR Clinical Guidelines Flawed by Low Evidence

JAMA Internal Medicine has reported that recommendations and clinical practice guidelines from the American College of Rheumatology are often based on expert opinion, but lack rigorous (grade A) evidence to support many of their recommendations. 

RheumNow ACR 2017 Awards

The Annual Meeting of the American College of Rheumatology is a gargantuan educational and professional event that is on nearly everyone's radar each year. RheumNow had an expansive effort to cover this meeting and you can review the work of our faculty at ACR17.RheumNow.com.  But we have decided to take this one step further and today we are announcing our 2017 RheumNow ACR Awards.